Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SAR443579 |
Synonyms | |
Therapy Description |
SAR443579 is a trispecific natural killer (NK) cell engager (NKCE) comprised of antibodies targeting tumor-expressed CD123, and the NK-cell specific receptors NKp46 and CD16, potentially leading to NK cell-mediated killing of tumor cells expressing CD123 (J Clin Oncol 41, 2023 (suppl 16; abstr 7005)). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SAR443579 | SAR-443579|SAR 443579|IPH 6101|IPH-6101|IPH6101 | SAR443579 is a trispecific natural killer (NK) cell engager (NKCE) comprised of antibodies targeting tumor-expressed CD123, and the NK-cell specific receptors NKp46 and CD16, potentially leading to NK cell-mediated killing of tumor cells expressing CD123 (J Clin Oncol 41, 2023 (suppl 16; abstr 7005)). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05086315 | Phase Ib/II | SAR443579 | First-in-human Study of SAR443579 Infusion in Male and Female Participants of at Least 12 Years of Age With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) | Recruiting | USA | NLD | FRA | AUS | 1 |